EZH2 and hemoglobin measurement: Taken together, our data support a model in which EZH2 overexpression drives HB tumor progression through both canonical and noncanonical mechanisms, associated with dysregulated mitosis, altered PRC2 complex integrity, and potential epigenetic modulation of CDH1 signaling.